BriSTAR Immunotech Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
100
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$29.5M
- Investors
-
18
BriSTAR Immunotech General Information
Description
Manufacturer of engineered T-cell immunotherapy products designed to treat cancer, autoimmune disorders, and other complex diseases. The company offers proprietary STAR-T and TCR-T platforms with multi-target engagement and enhanced tumor infiltration, enabling patients and healthcare providers to achieve improved treatment outcomes in difficult-to-treat conditions.
Contact Information
Website
www.bristarimmunotech.comCorporate Office
- 5th Floor, Building 4, Medical Technology Center, Life Science Park
- Changping District
- Beijing, 102206
- China
Corporate Office
- 5th Floor, Building 4, Medical Technology Center, Life Science Park
- Changping District
- Beijing, 102206
- China
BriSTAR Immunotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC (Series C) | 06-Jul-2026 | $29.5M | Completed | Generating Revenue | ||
| 10. Early Stage VC (Series B1) | 15-Jul-2022 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Private | 24-Feb-2022 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Private | 03-Dec-2021 | Completed | Generating Revenue | |||
| 7. Early Stage VC (Series B) | 23-Sep-2021 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 25-May-2021 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 26-Jan-2021 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A1) | 01-Jan-2020 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 21-Dec-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 30-Aug-2018 | Completed | Generating Revenue |
BriSTAR Immunotech Signals
BriSTAR Immunotech Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Loyal Valley Capital | Growth/Expansion | Minority | ||
| Shanghai Fudan Science Park Venture Capital | Venture Capital | Minority | ||
| Tsinghua Holdings Capital | Growth/Expansion | Minority | ||
| Yuanhui Investment | Growth/Expansion | Minority | ||
| Beijing Changkejin Investment | Growth/Expansion | Minority |
BriSTAR Immunotech FAQs
-
When was BriSTAR Immunotech founded?
BriSTAR Immunotech was founded in 2018.
-
Where is BriSTAR Immunotech headquartered?
BriSTAR Immunotech is headquartered in Beijing, China.
-
What is the size of BriSTAR Immunotech?
BriSTAR Immunotech has 100 total employees.
-
What industry is BriSTAR Immunotech in?
BriSTAR Immunotech’s primary industry is Drug Discovery.
-
Is BriSTAR Immunotech a private or public company?
BriSTAR Immunotech is a Private company.
-
What is BriSTAR Immunotech’s current revenue?
The current revenue for BriSTAR Immunotech is .
-
How much funding has BriSTAR Immunotech raised over time?
BriSTAR Immunotech has raised $81.7M.
-
Who are BriSTAR Immunotech’s investors?
Loyal Valley Capital, Shanghai Fudan Science Park Venture Capital, Tsinghua Holdings Capital, Yuanhui Investment, and Beijing Changkejin Investment are 5 of 18 investors who have invested in BriSTAR Immunotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process